Literature DB >> 12224720

Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy.

James M Wilson1, Rollo P Villareal, Ramesh Hariharan, Ali Massumi, Raja Muthupillai, Scott D Flamm.   

Abstract

Myocardial fibrosis can occur in patients who have hypertrophic cardiomyopathy in the absence of epicardial coronary disease. In such patients, myocardial fibrosis has been linked to a poorer prognosis than in those without fibrosis. Gadolinium-DTPA delayed-enhancement magnetic resonance imaging (de-MRI) accurately identifies regions of myocardial fibrosis. We used de-MRI to screen for myocardial fibrosis in 8 patients with nonobstructive hypertrophic cardiomyopathy that had been diagnosed by 2-dimensional echocardiography. After localization of the heart and acquisition of electrocardiographically gated cine images, gadolinium-DTPA (0.2 mmol/kg) was administered to the patient. Fifteen minutes later, de-MRI images were obtained using a T1-weighted, inversion-recovery fast, low-angle shot sequence. Images were gated to end-diastole and obtained during a single breath-hold. The inversion time was modified iteratively to obtain maximal nulling of the signal from the ventricular myocardium. Regions of myocardium with abnormally high signals (>300% of remote normal myocardium) were designated as fibrotic. Eight patients with hypertrophic cardiomyopathy underwent de-MRI. The mean age was 52 years, the mean left ventricular mass was 201 grams, and the mean ejection fraction was 0.68. In the 6 patients with recent clinical deterioration, de-MRI showed clearly delineated areas of myocardial fibrosis; no such areas were seen in the 2 asymptomatic patients. We conclude that patients with symptomatic hypertrophic cardiomyopathy display regions of abnormal signal intensity on de-MRI that likely represent fibrosis. This technique may provide useful information in the evaluation of such patients and warrants further study.

Entities:  

Mesh:

Year:  2002        PMID: 12224720      PMCID: PMC124756     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  19 in total

1.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  J Shirani; R Pick; W C Roberts; B J Maron
Journal:  J Am Coll Cardiol       Date:  2000-01       Impact factor: 24.094

2.  Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia.

Authors:  B Schwartzkopff; M Mundhenke; B E Strauer
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

3.  Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation.

Authors:  R Krams; M J Kofflard; D J Duncker; C Von Birgelen; S Carlier; M Kliffen; F J ten Cate; P W Serruys
Journal:  Circulation       Date:  1998-01-27       Impact factor: 29.690

4.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.

Authors:  R J Kim; E Wu; A Rafael; E L Chen; M A Parker; O Simonetti; F J Klocke; R O Bonow; R M Judd
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

5.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

6.  Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy.

Authors:  M Tanaka; H Fujiwara; T Onodera; D J Wu; M Matsuda; Y Hamashima; C Kawai
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

7.  Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy.

Authors:  M Tanaka; H Fujiwara; T Onodera; D J Wu; Y Hamashima; C Kawai
Journal:  Br Heart J       Date:  1986-06

8.  Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures.

Authors:  R O Cannon; D R Rosing; B J Maron; M B Leon; R O Bonow; R M Watson; S E Epstein
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

9.  Thallium perfusion and cardiac enzyme abnormalities in patients with familial hypertrophic cardiomyopathy.

Authors:  S Nagata; Y Park; T Minamikawa; C Yutani; T Kamiya; T Nishimura; T Kozuka; H Sakakibara; Y Nimura
Journal:  Am Heart J       Date:  1985-06       Impact factor: 4.749

10.  Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients.

Authors:  B J Maron; W C Roberts; S E Epstein
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

View more
  16 in total

1.  Delayed Myocardial Enhancement in Pediatric Hypertrophic Cardiomyopathy: Correlation with LV Function, Echocardiography, and Demographic Parameters.

Authors:  Sonia El Saiedi; Noha Hossam Behairy; Ahmed Kharabish; Reem Esmail; Zeinab Salah Seliem; Mervat Shafik; Wesam El Mozy
Journal:  Pediatr Cardiol       Date:  2017-04-11       Impact factor: 1.655

2.  Cardiac magnetic resonance imaging in small rodents using clinical 1.5 T and 3.0 T scanners.

Authors:  Wesley D Gilson; Dara L Kraitchman
Journal:  Methods       Date:  2007-09       Impact factor: 3.608

Review 3.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

4.  Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping.

Authors:  Bo Da Nam; Sung Mok Kim; Hye Na Jung; Yiseul Kim; Yeon Hyeon Choe
Journal:  Int J Cardiovasc Imaging       Date:  2018-05-30       Impact factor: 2.357

5.  Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia.

Authors:  Justin P Zachariah; Steven D Colan; Peter Lang; John K Triedman; Mark E Alexander; Edward P Walsh; Charles I Berul; Frank Cecchin
Journal:  Circ Heart Fail       Date:  2012-05-24       Impact factor: 8.790

Review 6.  The emerging clinical role of cardiovascular magnetic resonance imaging.

Authors:  Andreas Kumar; David J Patton; Matthias G Friedrich
Journal:  Can J Cardiol       Date:  2010 Jun-Jul       Impact factor: 5.223

Review 7.  The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Martin S Maron
Journal:  J Cardiovasc Transl Res       Date:  2009-11-07       Impact factor: 4.132

Review 8.  Cardiovascular function and the veteran athlete.

Authors:  M Wilson; R O'Hanlon; S Basavarajaiah; K George; D Green; P Ainslie; S Sharma; S Prasad; C Murrell; D Thijssen; A Nevill; G Whyte
Journal:  Eur J Appl Physiol       Date:  2010-06-17       Impact factor: 3.078

9.  Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.

Authors:  Lucy E Hudsmith; Steffen E Petersen; Jane M Francis; Matthew D Robson; Hugh Watkins; Stefan Neubauer
Journal:  Int J Cardiovasc Imaging       Date:  2005-11-03       Impact factor: 2.357

10.  Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy.

Authors:  Shaji C Menon; Susan P Etheridge; Kirk N Liesemer; Richard V Williams; Tyler Bardsley; Mason C Heywood; Michael D Puchalski
Journal:  Pediatr Cardiol       Date:  2014-05-15       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.